ArticleMucosal immunology2010
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.
Article in Mucosal immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Engineering strategies and decision frameworks for virus-like particle-based vaccines against infectious diseases.Frontiers in microbiology · 2026Review
- Comparison of plant- and mammalian cell-produced human papillomavirus pseudovirions.Journal of virological methods · 2025Article
- Article
- Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcNature communications · 2017Article
- Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.International journal of molecular sciences · 2016Article
- Human papillomavirus capsids preferentially bind and infect tumor cells.International journal of cancer · 2016Article
- Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses.ACS biomaterials science & engineering · 2016Article
- Article
- Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.PloS one · 2015Article
- Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Virus-like particles for the prevention of human papillomavirus-associated malignancies.Expert review of vaccines · 2013Review
- Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.The Journal of clinical investigation · 2012Article
- Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia.Theoretical biology & medical modelling · 2012Article
- Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Clinical and vaccine immunology : CVI · 2012Article
- Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Respiratory syncytial virus vaccine development.Expert review of vaccines · 2011Review
- Genital delivery of virus-like particle and pseudovirus-based vaccines.Expert review of vaccines · 2011Article
- Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.Vaccine · 2011Article
- Aerosol delivery of virus-like particles to the genital tract induces local and systemic antibody responses.Vaccine · 2011Article
- HPV pseudovirions as DNA delivery vehicles.Therapeutic delivery · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Mucosal immunization may be important for protection against pathogens whose transmission and pathogenesis target the mucosal tissue. The capsid proteins of human papillomavirus (HPV) confer tropism for the basal epithelium and can encapsidate DNA during self-assembly to form pseudovirions (PsVs). Therefore, we produced mucosal vaccine vectors by HPV PsV encapsidation of DNA plasmids expressing an experimental antigen derived from the M and M2 proteins of respiratory syncytial virus (RSV). Intravaginal (IVag) delivery elicited local and systemic M-M2-specific CD8+ T-cell and antibody responses in mice that were comparable to an approximately 10,000-fold higher dose of naked DNA. A single HPV PsV IVag immunization primed for M-M2-specific-IgA in nasal and vaginal secretions. Based on light emission and immunofluorescent microscopy, immunization with HPV PsV-encapsidated luciferase- and red fluorescent protein (RFP)-expressing plasmids resulted in transient antigen expression (<5 days), which was restricted to the vaginal epithelium. HPV PsV encapsidation of plasmid DNA is a novel strategy for mucosal immunization that could provide new vaccine options for selected mucosal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.